ArticleJournal of gastroenterology2025
Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.
Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan.Advances in therapy · 2026Article
- Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study.The Lancet regional health. Western Pacific · 2026Article
- Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.Journal of gastroenterology · 2026Article
- Nutrition management and self-perceived relapse triggers in patients with inflammatory bowel disease: results from the 3R web-based survey.Crohn's & colitis 360 · 2026Article
- Distinct clinicopathological features of IgA nephropathy associated with Crohn's disease: comparison with ulcerative colitis and non-IBD IgA nephropathy.Clinical and experimental nephrology · 2026Article
- Canonical pathways and selective mechanisms of autophagy in inflammatory bowel disease.Advanced biotechnology · 2026Review
- Newly Diagnosed Crohn's Disease After SARS-CoV-2 Infection.Case reports in gastrointestinal medicine · 2026Article
- Underestimation of the horizontal extent of ulcerative colitis-associated neoplasia may lead to incomplete endoscopic resection and subsequent recurrence.Therapeutic advances in gastroenterology · 2026Article
- Nursing Care and Patient Education for Ulcerative Colitis Patients in Japan: A Scoping Review.Cureus · 2026Review
- Clinical Characteristics of Crohn's Disease-Associated Cancer with a Focus on Endoscopic Surveillance.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlmost a decade has passed since the previous nationwide survey on the prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in Japan was conducted in 2015. We conducted a new nationwide hospital-based survey to provide updated estimates of the patient numbers and prevalence rates of UC and CD in Japan in 2023.
methodsStratified random sampling was used to select hospital departments (internal medicine, surgery, pediatrics, and pediatric surgery) that routinely treat UC and CD patients. We sent questionnaires to the sampled departments to request sex-specific information on their patient numbers for UC and CD in 2023. Based on the responses, we estimated the annual patient numbers and prevalence rates of UC and CD throughout Japan. The estimates were compared with those from the previous 2015 survey.
resultsThe overall survey response rate was 50.8% (1,798/3,538 departments). The estimated patient numbers were approximately 316,900 (95% confidence interval: 223,900-409,900) for UC and 95,700 (61,100-130,400) for CD, both of which represent a 1.4-fold increase over the 8-year period since 2015. The annual prevalence rates per 100,000 population were 254.8 (male: 297.5; female: 214.4) for UC and 77.0 (male: 112.9, female: 43.0) for CD. The male-to-female ratios were 1.31 for UC and 2.49 for CD, and the UC-to-CD ratio was 3.31.
conclusionsThe patient numbers and prevalence rates of UC and CD have continued to steadily increase in Japan, suggesting the need for continued monitoring and further investigation to track the disease burden.
Indexed as
Identifiers
40892110What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.